Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Risk | Very High | - |
Rating | 2.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.33 | - |
NAV | ₹30.04 | - |
Fund Started | 20 Jun 2019 | - |
Fund Size | ₹818.33 Cr | - |
Exit Load | Exit load of 1% if redeemed within 30 days. | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 13.02% | - |
3 Year | 21.48% | - |
5 Year | 19.37% | - |
1 Year
3 Year
5 Year
Equity | 98.22% | - |
Cash | 1.78% | - |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 15.37% |
Cipla Ltd. | 8.09% |
Apollo Hospitals Enterprise Ltd. | 7.24% |
Torrent Pharmaceuticals Ltd. | 6.49% |
Abbott India Ltd. | 5.97% |
Aurobindo Pharma Ltd. | 5.13% |
Lupin Ltd. | 5.02% |
Fortis Healthcare Ltd. | 4.42% |
Ajanta Pharma Ltd. | 4.28% |
Ipca Laboratories Ltd. | 3.77% |
Name | Dhaval Joshi | - |
Start Date | 21 Nov 2022 | - |
Name
Start Date
Description | The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. | - |
Launch Date | 20 Jun 2019 | - |
Description
Launch Date